** Shares of Abbott India Ltd ABOT.NS climb 4.4% to 29,030 rupees
** JP Morgan ("overweight") lifts PT on stock to 34,000 rupees from 31,500 rupees, a Street-high, as per data compiled by LSEG
** Drugmaker's Q3 consol net profit jumped 16% Y/Y on Wednesday, stock jumped ~4%
** ABOT benefitted from its unique strategy of tailoring product launches to fit local markets, says JPM
** Adds, strong demand for Rybelsus, oral version of Novo Nordisk's NOVOb.CO weight-loss drug, boosted sales
** Avg rating of four analysts on ABOT at "strong buy"; median PT is 31,850 rupees - LSEG data
** Stock gained ~30% in 2024
(Reporting by Nandan Mandayam in Bengaluru)
((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。